Table 4.
Univariable analysis of imaging features and overall survival (significant findings)
| Univariate | ||
|---|---|---|
| HR | P | |
| Clinical | ||
| Age (continuous) | 1.00 | 0.033 |
| Age | 0.001 | |
| Symptom duration | 0.018 | |
| Chemotherapy | 0.46 | <0.001 |
| Midbrain extension | 1.36 | 0.008 |
| Extension Beyond Pons and BP | 1.64 | 0.002 |
| Extension Beyond Pons | 2.15 | 0.001 |
| AP Tumor dimension | 1.02 | 0.023 |
| Trans Tumor dimension | 1.01 | 0.031 |
| AP X Trans Tumor dimension | 1.00 | 0.029 |
| CC Tumor dimension | 1.01 | 0.009 |
| AP Tumor / AP pons ratio | 2.29 | 0.005 |
| AP X TR Tumor > AP X TR Pons | 1.30 | 0.012 |
| Enhancement (any) | 1.36 | 0.010 |
| Ring enhancement vs non-enhancing | 1.45 | 0.007 |
| Patchy enhancement vs non- enhancing | 1.44 | 0.005 |
| Patchy and ring enhancement vs non-enhancing | 1.93 | 0.001 |
| Diffusion restriction (any) | 1.46 | 0.003 |
| Hemorrhage (any) | 1.22 | 0.098 |
| Hemorrhage (GRE/SWI) | 1.43 | 0.028 |
| Necrosis (any) | 1.47 | 0.0006 |
| Necrosis + Ring Enhancement | 1.40 | 0.005 |
| Necrosis with no Ring Enhancement | 1.48 | 0.034 |
| Distant Disease | 2.95 | 0.0005 |
| Distant Disease (spine available) | 2.64 | 0.0031 |